exagen-logo-black.png
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
November 13, 2024 16:05 ET | Exagen Inc.
CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that management will participate in the following...
exagen-logo-black.png
Exagen Inc. Reports Third Quarter 2024 Results
November 12, 2024 08:00 ET | Exagen Inc.
Expanded AVISE® CTD trailing twelve-month average selling priceReduced Adjusted EBITDA loss for first three quarters of 2024Revenue in line with expectations, excluding one-time adjustments CARLSBAD,...
Exagen_Full_CMYK_Print_NoTagline 3.15.24.png
Exagen to Announce Third Quarter 2024 Results on November 12, 2024
October 29, 2024 16:05 ET | Exagen Inc.
CARLSBAD, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended September 30, 2024,...
Exagen_Full_CMYK_Print_NoTagline 3.15.24.png
Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence
October 21, 2024 16:05 ET | Exagen Inc.
CARLSBAD, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of five abstracts at the 2024 American College...
Exagen_Full_CMYK_Print_NoTagline 3.15.24.png
Exagen Inc. to Participate in the Canaccord Genuity 44th Annual Growth Conference
August 02, 2024 09:00 ET | Exagen Inc.
CARLSBAD, Calif., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Canaccord Genuity 44th...
Exagen_Full_CMYK_Print_NoTagline 3.15.24.png
Exagen to Announce Second Quarter 2024 Results on August 5, 2024
July 22, 2024 09:00 ET | Exagen Inc.
CARLSBAD, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended June 30, 2024, before...
Exagen_Full_CMYK_Print_NoTagline 3.15.24.png
Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year
May 13, 2024 08:00 ET | Exagen Inc.
CARLSBAD, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31,...
Exagen_Full_CMYK_Print_NoTagline 3.15.24.png
Exagen Announces Campaign for Lupus Awareness Month
May 06, 2024 16:05 ET | Exagen Inc.
CARLSBAD, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch...
Exagen_Full_CMYK_Print_NoTagline 3.15.24.png
Exagen Inc. Announces Changes to the Board of Directors
April 26, 2024 08:30 ET | Exagen Inc.
CARLSBAD, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced changes to the Board of Directors. Exagen is...
Exagen_Full_CMYK_Print_NoTagline 3.15.24.png
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results
March 18, 2024 08:00 ET | Exagen Inc.
CARLSBAD, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full...